Actinium Pharmaceuticals, Inc. (ATNM)
| Market Cap | 51.56M +27.0% |
| Revenue (ttm) | 35.09M |
| Net Income | 11.31M |
| EPS | 0.36 |
| Shares Out | 31.44M |
| PE Ratio | 4.61 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 180,622 |
| Open | 1.560 |
| Previous Close | 1.590 |
| Day's Range | 1.560 - 1.620 |
| 52-Week Range | 0.735 - 1.720 |
| Beta | 0.26 |
| Analysts | Strong Buy |
| Price Target | 4.00 (+143.9%) |
| Est. Earnings | Nov 27, 2026 |
About ATNM
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for ATNM stock is "Strong Buy." The 12-month stock price target is $4.0, which is an increase of 143.90% from the latest price.
News
Actinium Pharmaceuticals to Host KOL Webinar on ATNM-400, a First-in-Class HER3-Targeted Alpha Radiotherapy
Leading prostate cancer expert Michael J. Morris, MD, of Memorial Sloan Kettering Cancer Center, to discuss unmet needs in metastatic castration-resistant prostate cancer (mCRPC) and the potential for...
Actinium begins enrollment for Radianz clinical trial
Actinium Pharmaceuticals (ATNM) announced that the RADIANZ clinical trial is enrolling patients. RADIANZ is an imaging study of Zr-Barecetamab-DFO using PET to guide the pan-tumor development of Ac-Ba...
Actinium Pharmaceuticals Announces Enrollment in the RADIANZ Imaging Clinical Trial Intended to Demonstrate the Pan-Cancer Potential of ATNM-400, A First-in-Class HER3-Targeting Radiotherapy
RADIANZ results will inform ATNM-400 clinical development beyond prostate cancer to patients with advanced HER3-expressing solid tumors in multiple cancers Builds on initial first-in-human clinical da...
Actinium forms Scientific Advisory Board
Actinium Pharmaceuticals (ATNM) announced the formation of a Scientific Advisory Board comprising five distinguished clinicians and scientists with extensive experience in oncology, nuclear medicine a...
Actinium Pharmaceuticals Announces Formation of Scientific Advisory Board Featuring Leading Experts in Oncology and Radiopharmaceutical Development
Scientific Advisory Board brings together world-class expertise in prostate cancer, hematologic malignancies, molecular imaging, radiochemistry and clinical development Internationally recognized advi...
Actinium Pharmaceuticals Announces Three ASH 2026 Abstracts Highlighting Iomab-ACT Clinical Results in CAR T-Cell Therapy and Sickle Cell Disease
The three abstracts strengthen the clinical foundation for Iomab-ACT's development as a targeted conditioning platform for cellular and gene therapies across cancer and nonmalignant diseases Phase 1b/...
Actinium Pharmaceuticals Announces ASH 2026 Abstract Highlighting Long-Term Results of Actimab-A in Combination with CLAG-M in Relapsed or Refractory AML
Results report the safety of combining targeted alpha therapy with CLAG-M for patients with relapsed or refractory acute myeloid leukemia Long-term follow-up evaluates bone marrow recovery and potenti...
Actinium Pharmaceuticals Announces Acceptance of ATNM-400 Abstract for Presentation at SABCS 2026 Highlighting Activity Across Therapy-Resistant Breast Cancer Models
Poster presentation to highlight preclinical efficacy of ATNM-400 across therapy-resistant breast cancer subtypes ATNM-400 is a first-in-class targeted alpha therapy directed against HER3, a driver of...
Actinium Pharmaceuticals Announces Inducement Grant to New Employee
NEW YORK, Oct. 30, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced an ...
Actinium Pharmaceuticals to Highlight First-in-Human Phase 1 Study of ATNM-400 a HER3-Targeted Non-PSMA Radiotherapy in Prostate Cancer at ESMO 2026
First‑in‑human Phase 1 study evaluates HER3‑targeted ATNM‑400 in metastatic castration‑resistant prostate cancer population, including patients with and without prior PSMA‑directed therapy HER3‑target...
Actinium Pharmaceuticals’ ATNM-400 shows anti-tumor activity in prostate cancer
Actinium Pharmaceuticals (ATNM) announced “encouraging” initial clinical results from the first-in-human Phase 1 study of ATNM-400 in metastatic castration-resistant prostate cancer, or mCRPC. The fin...
Actinium Pharmaceuticals Unveils ATNM‑400 Data at EANM 2026 with a First‑In‑Human HER3‑Targeted Radiotherapy Approach Beyond PSMA in Prostate Cancer
HER3‑targeted PET imaging demonstrated tumor uptake and retention, supporting ATNM‑400's potential to deliver sustained alpha radiation to tumors over a timeframe consistent with Actinium‑225's 10-day...
Actinium Pharmaceuticals Presents EANM 2026 Results Reinforcing ATNM-400's Pan-Tumor Potential Across Lung, Colorectal and Ovarian Cancer Models
ATNM-400 demonstrated activity across EGFR-, KRAS- and ALK-driven lung cancer models, supporting mutation-agnostic development as monotherapy and in combination with established treatments In colorect...
Actinium Pharmaceuticals to Showcase ATNM-400's First-in-Human Clinical Data in Prostate Cancer and Preclinical Results in Lung Cancer Supporting Pan-Tumor Potential Today at EANM 2026
First-in-human Phase 1 presentation to feature ATNM-400 clinical data in metastatic castration-resistant prostate cancer, advancing a differentiated approach beyond PSMA Preclinical presentation to fe...
Actinium Pharmaceuticals Announces Inducement Grants to New Employees
NEW YORK, Oct. 16, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced ind...
Actinium Pharmaceuticals to present ATNM-400 data at EANM
Actinium Pharmaceuticals (ATNM) announced three presentations, including an oral presentation and two e-posters, highlighting preclinical data supporting ATNM-400’s broad potential at the 39th Annual ...
Actinium Pharmaceuticals Announces Oral and Poster Presentations at EANM 2026 Highlighting Broad Antitumor Activity of ATNM-400 Across Lung, Colorectal and Ovarian Cancer Models
Oral presentation to highlight ATNM-400 antitumor activity across KRAS- and ALK-driven NSCLC models, building on earlier EGFR-mutant findings and supporting mutation-agnostic development Colorectal ca...
Actinium Pharmaceuticals Proxy statement: Proxy filing
Actinium Pharmaceuticals filed a proxy statement on October 16, 2026, providing details for shareholder voting and corporate governance matters.
Actinium Pharmaceuticals Appoints Radiopharmaceutical Industry Veteran Sean Maenpaa as Senior Vice President, Business Development
– Brings more than 20 years of oncology business development and commercial leadership, including senior roles across the radiopharmaceutical sector at Bayer, Clovis Oncology, Telix Pharmaceuticals an...
Actinium Pharmaceuticals Announces Oral Presentation at EANM 2026 Highlighting First-in-Human Phase 1 Study of ATNM-400, a Non-PSMA Targeting Radiotherapy, in Prostate Cancer
Early clinical data from the Phase 1 theranostic trial support the advancement of ATNM-400 as a non-PSMA targeted alpha therapy for metastatic castration-resistant prostate cancer (mCRPC) Evaluation o...
Actinium Pharmaceuticals appoints Matt David as CFO
Actinium Pharmaceuticals (ATNM) appointed Matt David as CFO. David joins Actinium from CorMedix, where he most recently served as EVP and Chief Business Officer. He joined CorMedix in 2020 as…
Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced the...
Actinium Pharmaceuticals Slides: Investor presentation
Actinium Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on October 1, 2026.
Actinium Pharmaceuticals, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference
NEW YORK, Sept. 4, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that Sa...
Actinium Pharmaceuticals Slides: Investor presentation
Actinium Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on September 2, 2026.